Factors Affecting the Improvement of the Initial Peak Urinary Flow Rate after Transurethral Resection of the Prostate or Photoselective Vaporization of the Prostate for Treating Benign Prostatic Hyperplasia.
- Author:
Hwa Sub CHOI
1
;
Dong Jun KIM
;
Dong Suk KIM
;
Kyoung Pil JEON
;
Tae Yoong JEONG
Author Information
1. Department of Urology, Kwandong University College of Medicine, Goyang, Korea. urojeong@kwandong.ac.kr
- Publication Type:Original Article
- Keywords:
Transurethral resection of the prostate;
Laser therapy;
Prostatic hyperplasia
- MeSH:
Ambulatory Care Facilities;
Body Mass Index;
Humans;
Laser Therapy;
Prostate;
Prostate-Specific Antigen;
Prostatic Hyperplasia;
Pyuria;
Quality of Life;
Transurethral Resection of Prostate;
Urinary Retention;
Volatilization
- From:International Neurourology Journal
2011;15(1):35-40
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We evaluated the factors that affect the improvement of the initial peak flow rate after transurethral resection of the prostate (TURP) or photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) patients by using noninvasive tools. METHODS: One hundred and twenty seven BPH patients who had undergone TURP or PVP between January 2005 and May 2009 were evaluated. They were divided into 2 groups: the postoperative initial peak urinary flow rate (Qmax) was less than 10 mL/sec (Group 1; n=37, TURP=11, PVP=26) and more than 10 mL/sec (Group 2; n=90, TURP=41, PVP=49). We confirmed the patients' preoperative check lists. The check list were the international prostate symptom score (IPSS), the quality of life score, a past history of acute urinary retention (AUR), body mass index and/or pyuria, the serum prostate-specific antigen (PSA) level and the prostate volume, the prostate transitional zone volume and prostatic calcification. The initial Qmax was measured at the outpatient clinic one week after discharge. RESULTS: The improvement rate was not significant difference between the TURP group (78.8%) and the PVP group (65.3%). The efficacy parameters were the IPSS-storage symptom score, the prostate volume, the PSA level and a past history of AUR. The IPSS-storage symptom scores of Group 1 (12.3+/-3.3) was higher than those of Group 2 (10.5+/-1.7). The prostate volume of Group 2 (42.3+/-16.6 g) was bigger than that of Group 1 (36.6+/-7.8 g). The PSA level of Group 2 (3.8+/-2.6 ng/mL) was higher than that of Group 1 (2.6+/-2.6 ng/mL). A past history of AUR in Group 1 (35.1%) was more prevalent than that of Group 2 (15.6%). CONCLUSIONS: The non-invasive factors affecting the initial Qmax after TURP or PVP were the IPSS-storage symptom score, the prostate volume and a past history of AUR. Accordingly, in patients who have a higher IPSS-storage symptom score, a smaller prostate volume and a history of AUR, there might be a detrimental effect on the initial Qmax after TURP or PVP. These factors might also be used as long-term prognostic factors.
